Gain Access to exclusive preclinical content.
Complete the form below to gain access to mattis aliquet nunc aliquam tempor. We’ll assign a user name and password, then send you a link. Thanks!

Get Access Register

EXCLUSIVE PRECLINICAL CONTENT.
You must log in to access content on this page. Or click here to request access.
A multicenter blinded preclinical randomized controlled trial on Jak1/2 inhibition in MRL/MpJ-Faslpr mice with proliferative lupus nephritis predicts low effect size

Yutian Lei, Bettina Sehnert PhD, Reinhard E.Voll MD, Conxita Jacobs-Cach PhD, Maria Jose Soler MD, PhD, Maria D. Sanchez-Niño PhD, Alberto Ortiz MD,PhD, Roman D. Bülow MD, Peter Boor MD,PhD, Hans-Joachim Anders MD, "A multicenter blinded preclinical randomized controlled trial on Jak1/2 inhibition in MRL/MpJ-Faslpr mice with proliferative lupus nephritis predicts low effect size", Kidney International, 16 February, 2021, https://doi.org/10.1016/j.kint.2021.01.024.